Mid-size Drugs Based on Peptides and Peptidomimetics A New Drug Category /

This brief describes studies conducted by the authors on mid-size drugs utilizing peptides and peptidomimetics, and on the development of anti-HIV agents. Peptides are important biological molecules and have various physiological actions. Peptide-based drug discovery may help bring about the develop...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Tamamura, Hirokazu (Συγγραφέας, http://id.loc.gov/vocabulary/relators/aut), Kobayakawa, Takuya (http://id.loc.gov/vocabulary/relators/aut), Ohashi, Nami (http://id.loc.gov/vocabulary/relators/aut)
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Singapore : Springer Singapore : Imprint: Springer, 2018.
Έκδοση:1st ed. 2018.
Σειρά:SpringerBriefs in Pharmaceutical Science & Drug Development,
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 03742nam a2200517 4500
001 978-981-10-7691-6
003 DE-He213
005 20191023181854.0
007 cr nn 008mamaa
008 180116s2018 si | s |||| 0|eng d
020 |a 9789811076916  |9 978-981-10-7691-6 
024 7 |a 10.1007/978-981-10-7691-6  |2 doi 
040 |d GrThAP 
050 4 |a RS400-431 
072 7 |a PSB  |2 bicssc 
072 7 |a SCI013020  |2 bisacsh 
072 7 |a PSB  |2 thema 
082 0 4 |a 615.19  |2 23 
100 1 |a Tamamura, Hirokazu.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
245 1 0 |a Mid-size Drugs Based on Peptides and Peptidomimetics  |h [electronic resource] :  |b A New Drug Category /  |c by Hirokazu Tamamura, Takuya Kobayakawa, Nami Ohashi. 
250 |a 1st ed. 2018. 
264 1 |a Singapore :  |b Springer Singapore :  |b Imprint: Springer,  |c 2018. 
300 |a XVII, 100 p. 40 illus., 32 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a SpringerBriefs in Pharmaceutical Science & Drug Development,  |x 1864-8118 
505 0 |a 1. Introduction of Mid-Size Drugs and Peptidomimetics -- 2. Chloroalkene Dipeptide Isosteres as Peptidomimetics -- 3. Conformational-restricted Cyclic Peptides -- 4. Peptidomimetics that Mimic Secondary Structures of Peptides -- 5.Peptidomimetics that Mimic Tertiary Structures of Peptides -- 6. Conjugated Compounds Involving Peptides -- 7. Summary and Future Perspectives of Researches on Mid-Size Drugs. 
520 |a This brief describes studies conducted by the authors on mid-size drugs utilizing peptides and peptidomimetics, and on the development of anti-HIV agents. Peptides are important biological molecules and have various physiological actions. Peptide-based drug discovery may help bring about the development of useful medicines that are highly safe and show potent pharmacological effects in small doses. Recently, it has been shown that there is an important drug-like space in the mid-sized region between low- and high-molecular-weight compounds. Thus, mid-size drugs such as peptide compounds are being focused on. To date, several peptidomimetics that mimic primary, secondary, and tertiary structures of peptides have been developed to maintain and improve biological activities and actions of peptides. In this book, the features and advantages of mid-size drugs are described in detail. In addition, the merits of utilizing peptidomimetics in the development of mid-size drugs are referred to. Understanding such peptide-derived mid-size drugs will lead to a comprehensive expansion of medicinal chemistry. 
650 0 |a Medicinal chemistry. 
650 0 |a Pharmaceutical technology. 
650 0 |a Organic chemistry. 
650 1 4 |a Medicinal Chemistry.  |0 http://scigraph.springernature.com/things/product-market-codes/C28000 
650 2 4 |a Pharmaceutical Sciences/Technology.  |0 http://scigraph.springernature.com/things/product-market-codes/B21010 
650 2 4 |a Organic Chemistry.  |0 http://scigraph.springernature.com/things/product-market-codes/C19007 
700 1 |a Kobayakawa, Takuya.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
700 1 |a Ohashi, Nami.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9789811076909 
776 0 8 |i Printed edition:  |z 9789811076923 
830 0 |a SpringerBriefs in Pharmaceutical Science & Drug Development,  |x 1864-8118 
856 4 0 |u https://doi.org/10.1007/978-981-10-7691-6  |z Full Text via HEAL-Link 
912 |a ZDB-2-SME 
950 |a Medicine (Springer-11650)